Key debates shaping health discourse in early 2026

“The most predictable reaction to GLP-1s isn’t from patients—it’s from parts of the fitness industry. Because GLP-1s don’t just change weight. They change the business model. If your entire brand is built on ‘just cut carbs harder,’ ‘just grind more,’ or selling willpower as a subscription service—then a medication that quiets hunger and improves metabolic signaling is… disruptive. So instead of adapting, some mock. They call patients ‘lazy.’ They call physicians ‘drug dealers.’ They pretend biology is a moral issue. But here’s the reality: Obesity isn’t a failure of effort. It’s a dysregulation of appetite, satiety, and energy balance. And medications like Ozempic don’t replace lifestyle—they make it possible.”

@drterrysimpson · Surgeon · bariatric medicine · 2026-03-22

“GLP-1s are not a weight-loss trend. They are a cultural earthquake. The uncomfortable question: Are GLP-1s helping patients reclaim control over their health, or are we building the next forever-rent business model in American medicine? Maybe the answer is both. And that is exactly why this topic matters.”

@AIHealthUncut · Sergei Polevikov · digital health analyst · 2026-05-08

“A landmark study published in Nature, involving over 160,000 patients, has exposed the horrific mental health toll of these drugs. The findings are nothing short of catastrophic for users. The research showed that individuals on GLP-1 agonists faced a 98% increased risk of being diagnosed with a psychiatric disorder compared to non-users. The risks for specific conditions were even more harrowing: a 195% higher risk of major depression and a 106% elevated risk of suicidal behavior.”

@HealthRanger · Health commentator · 2026-02-04

“🚨 Medical AI has an evidence problem. Not a performance problem. An evidence problem. A brilliant Nature Medicine editorial says what many people avoid saying: Stop showing us AUROC. Show us clinical value. Because: sensitivity, specificity, calibration, benchmark performance…do not prove better patient care. A model can be technically excellent and still be: ❌ clinically useless ❌ workflow-disruptive ❌ dangerously misleading.”

@FCademartiri · Dr. Filippo Cademartiri · cardiologist, medical imaging researcher · 2026-04-26

“One of the biggest fears about healthcare’s AI revolution is that AI can erode physicians’ expertise and their performance may drop when AI is removed. A new scoping review provides examples for that. In colonoscopy, the adenoma detection rate dropped significantly from 28.4% to 22.4% when endoscopists reverted to non-AI procedures after repeated AI use. In radiology, erroneous AI prompts increased false-positive recalls by up to 12%, even among experienced readers.”

@Berci · Berci Meskó, MD, PhD · medical futurist · 2026-03-23

“Every few months, someone rediscovers the idea that radiologists are about to become obsolete and I have to waste an hour writing an evidence based LinkedIn/X rebuttal. Wrote an evidence-backed response to the NYC hospital CEO who said yesterday that he wants to replace radiologists with AI. Covers the Hinton prophecy that failed, our RadLE benchmark data (best AI: 57%, radiologists: 83%), and why hospital administration is probably more automatable than diagnosis.”

@DrDatta_AIIMS · Dr. Datta · radiologist, AIIMS · 2026-04-01

“The longevity industry is a scam. It sells over-testing, over-medicating, and over-supplementing at obscene prices. All for a promise that can’t be validated for another 50 years. You’re paying a premium for a hypothesis. Meanwhile, the actual formula for a long life isn’t a secret: stay metabolically healthy. Don’t eat garbage. Eat real, essential food. Move. Rest. Manage stress. Have real friendships. Laugh. Build something with people you love.”

@ElieJarrougeMD · Elie Jarrouge, MD · physician · 2026-02-19

“Longevity 2.0: Your next doctor won’t prescribe pills—they’ll prescribe gene therapies, epigenetic reprogramming, and personalized longevity protocols. Medicine is shifting from ‘treat symptoms’ to ‘reverse aging at the cellular level.’”

@PeterDiamandis · Peter H. Diamandis, MD · entrepreneur, longevity advocate · 2026-04-01

“Truth-seeking is hard. When randomized trials are hard to run, it’s tempting to cut corners. Longevity RCTs would be extremely expensive and long-horizon. Few can afford them, and so more and more we present correlations and unproven biomarkers or surrogates as ‘biological age.’ N=1 experiments work when the readout is clear. But the risk here is taking black-box numbers trained on population averages without intervention data, and redesigning our lives based on them. Longevity science needs faster ways to learn, but faster still needs to be Good.”

@MartinBJensen · Martin Borch Jensen · aging researcher · 2026-05-06

“Stigmatizing psychiatric medications from a federal leadership position while simultaneously reducing access to actual mental health care is reckless. Medical policy should be guided by evidence, trained specialists & clinical outcomes. Not ideology & anti medicine rhetoric.”

@socrdoc · Suzy McNulty, MD · physician, policy critic · 2026-05-06

“Mental health care just crossed a line. In 2024, FDA cleared Rejoyn, the first prescription digital therapeutic for major depressive disorder. In 2025, WHO put mental disorders above 1B people worldwide. Access is broken and software is entering treatment. This is not wellness-app hype. Medicare now covers FDA-cleared digital mental health devices within care plans. That shifts payer models, workflows and competition. The mandate: prove outcomes, protect data, and avoid a two-tier system.”

@sciqst · Raffaele Di Giacomo, PhD · health technology researcher · 2026-05-07

“What used to count as preventive medicine in 1926: Eat whole foods, Move every day, Sleep when it gets dark, Get sunlight, Stay connected to your community, Have purpose. What counts as preventive medicine in 2026: Daily statin, Annual flu jab, Annual colonoscopy from 45 onwards, Annual mammogram, Annual blood panel that nobody explains to you, A prescription for a condition you may develop in 20 years. Notice that the second list costs money, requires a clinic, generates billable codes, and produces revenue. The first list does none of those things.”

@SamaHoole · Sama Hoole · health systems commentator · 2026-04-30

“The issue isn’t obesity per se, it’s about the lifestyle choices they make. I have nothing against GLP-1s when used thoughtfully. For some people, they’re life savers. But in a few years from now, the people who took them to lose weight only to look better while still being able to eat junk food or eat to excess will be the first ones complaining about side/adverse effects.”

@AmericanEpilog · Mona · integrative health advocate · 2026-05-05